The management of therapy was done according to genotyping test results, with therapeutic regimen alterations done in 16 from the 18 antiretroviral-resistant children, while on the period of study observation. Therapeutic regimen modification was also done for one child among the seven who showed no antiretroviral resistance evidence. HIV-1 viral load determinations and CD4+ and CD8+ T cell measurements were done for each child at varied intervals, during different followed-up periods ranging from 9 months to 33 months (average 17.4 months), except for one child without return to the clinical visits, followed-up only for 3 months. Laboratorial data evaluation for viral load and T lymphocyte subsets, referred to child's inclusion in the study, were defined as those most close to blood drawn date for genotyping test evaluation.
In order to normalize the data comparison, viral load drop evaluation was calculated in a logarithmic scale, considering the difference between viral load initial value, equivalent to the child inclusion in the study, and the consecutive value registered after the antiretroviral regimen modification. Adopted significant differences were those equal to 0.7 log 10 for pediatric patients aged up to two years old and 0.5 log 10 for those older than two years old.
The clinical classification for each child enrolled at this study was considered that related to the clinician evaluation done at the child inclusion date, irrespectively to its clinical course evolution. This classification, the viral load, CD4 and CD8 rates and the therapeutic regimen modifications are indicated in table 3. The evaluation of these same clinical and laboratorial data for the group of children with no therapeutic alterations is indicated in table 4. Table 3 . Clinical and laboratorial data from children on HAART therapy presenting drug regimen modification (continuation). period, showed a minor viral load decline (0.172 log 10 ), below the 0.5 log 10 limit. Twelve from the 16 children presented important viral load declines reaching RNA levels below the lower test limit, and two children presented viral load rebounds to the initial levels after they were receiving antiretroviral therapy lasting for more than 11 months.
Five children among 8 with no drug regimen alteration, showed viral load declines higher than 0.5 log 10 (average 2.481 log 10 ) and one child presented a nonsignificant viral load drop (0.225 log 10 ). Only polymorphisms or no relevant HIV-1 reverse transcriptase and protease mutations were detected in all the 6 children. The remaining 2 children, showing antiretroviral resistance, presented non-significant viral load declines (0.350 log 10 ) or viral load rises with 1.516 log 10 RNA rate difference. In summary, we observed that initiating or keeping antiretroviral regimen allowed the viral load reduction in 7 among the 8 children included in this group. In addition, RNA levels reached low levels, below the lower test limit in 4 of them, while they were on the study observation period.
CD4+T lymphocytes and HIV-associated immunodeficiency.
CD4+ T lymphocyte values used for HIV-associated immunodeficiency classification showed that, irrespectively to the child age, 8 from 25 children presented CD4 percentages lower than 15%, characterizing severe immunodeficiency. Seven children reported these low rates at the time of their first laboratorial evaluation as they were enrolled in this study and CD4 decreasing percentages were observed in a child during the followed-up period. Therapeutic regimen modification or its maintenance promoted increases in CD4 percentages in 4 among the 8 children, and in the remaining 4 we observed the following results: an important CD4 drop reaching 4.44% was observed in the child who died; in another child, followed-up for a three month period,
we could merely report a single CD4 percentage not allowing comparisons, and in 2 children we observed CD4 percentages lower than 15% for the entire followed-up period, coincident with elevated viral load levels.
In the remaining 17 children, CD4 evaluation was done according to the child age range, using CD4 percentages for children aging from 12 months to 59 months, and T CD4+/mL cell counts for those aging or older than 5 years old. Four children were included in the age group ranging from 12 months to 59 months, showing HIVassociated immunodeficiency level as follows: mild (1 child), advanced (1 child) and non-significant (2 children). In this group, alterations or the maintenance of the antiretroviral regimen resulted in CD4 percentage increases in the three children presenting mild or non-significant immunodeficiency levels, promoting the change of the mild level to non-significant one or the maintenance of the non-significant level during the entire followed-up study. The forth child, presenting CD4 percentages equal to 18.48 and 16.0, compatible with HIV-associated advanced immunodeficiency, showed only minimum decreases or raises in the viral load rates, with values ranging from 4.480 log 10 to 5.342 log 10 . In the 13 children group, aging or older than 5 years old, the HIV-associated immunodeficiency level distribution according to CD4 cell counts was seen as follows: advanced (1 child), mild (3 children), and non-significant (9 children). In the 4 children presenting advanced or mild immunodeficiency, alterations or the maintenance of the antiretroviral regimen resulted in a level change to the nonsignificant status, with an increase in the CD4 T cell counts. Seven children among the 9 who presented non-significant immunodeficiency level maintained the same immunodeficiency level, showing CD4 cell counts raises or only minor fluctuations.
However, 2 children presenting HIV-associated non-significant immunodeficiency level had their immunodeficiency status changed to the mild level. One of them, to whom some antiretroviral regimen modification was done, showed viral load decreases reaching undetectable levels, and the second one who had no therapy regimen alterations, reported increasing HIV-1 viral loads.
Although CD4+ T lymphocyte counts or percentages had indicated in the majority of the children an improvement of their HIV-associated immunodeficiency level, CD8+ T lymphocyte counts constantly remained elevated or presented only minor fluctuations, rendering CD4/CD8 ratios lower than 1 in 20 from the 25 children included in this study.
DISCUSSION
The advent of highly active antiretroviral treatment (HAART) in the HIVinfected children and adults therapy has resulted in a significant longer life expectancy and an important delay in disease progression. (Gortmaker et al. 2001) .The availability and use of HAART has promoted marked declines in mortality and morbidity rates reported in recent years (Gona et al. 2006; McConnell et al. 2005) . However, it is hard to reach complete virus suppression in HIV-infected people due to multiple factors such as poor adherence to medication, drug intolerability, drug interactions or at inadequate levels. The virological response strongly depends on the previous drug history, reflecting previous selection of drug-resistant viral mutants as a result of suboptimal therapy.
Despite initial promising results, lasting for several years in many children, treatment failure has been frequently reported requiring reassessment of treatment options. HIV genotypic resistance determinations may be helpful, monitoring drug resistance at the time of therapy failure or prior to therapy initiation (Hirsch et al. 2000) .
Information on patterns of resistance is important for decisions on how to combine drugs to achieve an optimum antiviral effect. In the present study, we observed an important decline of viral burden in 17 children, most of them multi-drug resistant, who had alternative therapeutic options based on HIV-1 resistance genotype test results.
Undetectable levels were reached in 12 of them. In 7 from the remaining 8 children, with 6 showing no evidence of drug resistance, the introduction of HAART or keeping the previous antiretroviral therapy regimen allowed a significant reduction of viral load, mainly for those pediatric patients who were drug treatment naïve initiating therapy as they were enrolled at this study.
With regard to virus-specific CD4 T cells, it is well established their critical role in antiviral immunity, keeping effective cytotoxic T lymphocyte responses (Sherdlock & Shen 2003; Janssen et al. 2003) . In untreated HIV-infected people, HIV infection develops with early and massive depletion of these cells (Wahren et al. 1987; Douek et al. 2002) 
